Research Article Details
| Article ID: | A27797 |
| PMID: | 17405346 |
| Source: | Eur Rev Med Pharmacol Sci |
| Title: | Influence of insulin resistance in obese patients on elevated serum alanine aminotransferase. |
| Abstract: | BACKGROUND AND OBJECTIVE: Insulin resistance has been associated with fat liver and non-alcoholic fatty liver disease. The aim of our study was to study the influence of insulin resistance in obese patients on elevated serum alanine aminotransferase. RESEARCH METHODS: A population of 91 obesity non diabetic outpatients was analyzed in a cross sectional study. HOMA-IR was calculated as indicator of insulin resistance. RESULTS: The mean age was 39.2 +/- 16.7 years and the mean BMI 34.4 +/- 5.2. Patients were classified as group I (control, n=74) when serum (Alanine Aminotransferase) ALT activity was normal or group II (NAFLD, n=17) when serum ALT activity was greater than the upper limit of normal reference laboratory (> or =43 UI/L). Waist circumference, fat mass and hip to waist ratio were higher in group II. Insulin (13.5 +/- 7.8 mUI/L vs 24.9 +/- 16.7 mUI/L; p < 0.05), HOMA-IR (1.9 +/- 1.1 vs 3.9 +/- 2.8), and triglycerides levels (115.1 +/- 66.8 mg/dl vs. 153.2 +/- 71.2 mg/dl; p < 0.05) were higher in group II than group I. In the logistic regression analysis with a dependent dicotomic variable (ALT; group I and group II), the HOMA-IR remained in the model, with an Odd's Ratio to develop ALT >43 U/L of 2.18 (CI:95%: 1.12-4.2) with each 1 unit of HOMA-IR adjusted by age, sex, weight, and dietary intake. CONCLUSION: Insulin resistance in obese patients is associated with ALT activity. Further study is needed to evaluate histological changes and new treatments in these patients. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D545 | Pig placenta extract | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |